Campaigners want FDA to focus on women's sexual health

Share this article:
Campaigners want FDA to focus on women's sexual health
Sprout is among the groups lobbying the FDA for sexual parity

A coalition of health groups is lobbying for the FDA to give the same amount of attention to female sexual dysfunction disorders as it does to men's in a campaign titled Even the Score: A Campaign for Women's Sexual Health Equity.

The kick-off announcement noted that its June 4 announcement “comes less than a week after the FDA approved a 26th drug to treat the most common form of men's sexual dysfunction,” referring to the testosterone replacement drug Natesto.

“Gender equality should be the standard when it comes to access to treatments for sexual dysfunction; and the approval of safe and effective treatments for women's sexual dysfunction should be a priority for action by the FDA,” chair emeriti Susan Scanlan said  a statement.

Sprout Pharmaceuticals, which has an experimental treatment for hypoactive sexual desire disorder – marked by a lack of interest in sex and/or fantasies – is among the campaign's supporters, as are Palatin Technologies, the National Council of Women's Organizations, American Sexual Health Association and the Society for Women's Health Research, among others.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...